

Led by a visionary executive team, the Ceribell Point-of-Care EEG system is the first critical care EEG and quickly becoming an important vital sign for the brain.



## Jane Chao, PhD

### CEO and Co-founder

Jane Chao, the co-founder and CEO of Ceribell, holds a Ph.D. in biophysics from Cornell University. Before she joined Ceribell, Jane had a solid history of leadership and success in business. She launched her career as a management consultant with McKinsey & Company, and later made her move into the medical space joining Novartis as their Senior Strategy Manager. She then enjoyed a successful career at Genentech as their Principal Manager of Portfolio Management Strategy. In 2015, Jane started working at Ceribell full-time as the CEO, the position she currently holds. She has built and led the Ceribell team from early concept stages to a fully commercial, FDA-cleared, clinically proven and highly successful commercial product that is changing the standard of care for critically ill patients.



## Raymond Woo, PhD

### CTO

Raymond Woo joined Ceribell in 2016 to lead its product research and development efforts. Throughout his career, Ray has worked to successfully bring innovative and disruptive medical device technologies to market. Prior to Ceribell, he was Global Head of Femtosecond Laser R&D at Abbott Medical Optics (now a part of J&J Vision), where he was responsible for R&D efforts across multiple product lines in both the laser cataract surgery and the laser vision correction markets. He helped to develop the Catalys laser cataract surgery system at Optimedica, which was acquired by Abbott Medical Optics. Ray received a Ph.D. and Master's degree in Electrical Engineering from Stanford University, where his research focused on novel semiconductor devices. He has a Bachelor's degree in Electrical Engineering and Computer Science from Duke University.



## Scott Blumberg

### CFO

Scott Blumberg, Ceribell's CFO, has over 15 years of healthcare finance experience, largely focused on the medical device space. Prior to joining Ceribell, Scott served as Managing Advisor of Venture Forward Advisory Services, a financial and strategic consulting agency that he founded. At Venture Forward, served as a trusted advisor and outsourced CFO to 20+ venture-backed startups and emerging growth companies, completing over 100 engagements. Previously, Scott served as Director of Business Development for IDEV Technologies, a Houston based venture-backed medical device company, where he led strategic initiatives including implementing an advanced sales analytics program, sourcing and negotiating multiple partnerships, developing marketing strategies, and leading the M&A process that resulted in a \$310 million sale to Abbott. Scott previously served as investment professional at Bay City Capital, a San Francisco based life sciences venture capital firm, and an investment banking analyst at Bank of America. Scott holds a BA in economics with a minor in psychology from Dartmouth College.



## Baharan Kamousi, PhD

### VP of Data Science

Baharan Kamousi, Ceribell's VP of Data Science, joined Ceribell in 2017 with over 15 years of algorithm design experience for various medical applications spanning from Brain-Computer Interface, bioelectricity and audiometry to diagnostic and treatment algorithms for chronic diseases such as cardiac arrhythmias and heart failure, chronic pain, urinary incontinence and brain stimulation. She started her career at St. Jude Medical in the clinical systems engineering department where she gained extensive experience in all aspects of medical device and algorithms product lifecycle for various cardiovascular and neuromodulation applications and later joined a start-up company, Element Science, to design a machine learning algorithm for a wearable cardioverter defibrillator for patients at high risk of sudden cardiac arrest. Baharan holds a Bachelor's degree in Electrical Engineering from Sharif University of Technology and has completed her Master's and Ph.D. programs at University of Minnesota ECE department and as a visiting researcher at Stanford University, School of Medicine.



## Chris Cera

### VP of New Account Acquisition Sales

Chris Cera, Ceribell's VP of New Account Acquisition Sales, has over 20-years of sales and leadership experience in successful, early-stage medical device start-up and publicly traded companies. At Ceribell, Chris was previously Director of Sales, Regional Manager of the Year, Territory Manager of the Year and Rookie of the Year. He has been instrumental in developing Ceribell's sales playbook, recruiting, hiring and developing Ceribell's top performers and leaders in both sales organizations. Prior to Ceribell, Chris was at Medivance, acquired by C.R. Card for 250M. At Medivance, he led commercial Neuro sales and built the company's Neuro Peer to peer education program. Prior to Ceribell, Chris was one of the first sales leaders hired at AccessClosure, Inc., acquired by Cardinal Health for 320M. Chris holds a BA in English from Susquehanna University.

Led by a visionary executive team, the Ceribell Point-of-Care EEG system is the first critical care EEG and quickly becoming an important vital sign for the brain.



### Dan Rogy

#### VP of Operations

Dan Rogy, Ceribell's VP of Operation, has over 25 years of medical equipment and disposable device Operations and R&D management experience. He led the R&D and Operation Teams at Outset Medical to commercialize a novel Hemodialysis system. Dan was General Manager at Abbott Laboratories, after the acquisition of OptiMedica, where he was responsible for all medical capital equipment and disposable device operations. Previously he was Director of R&D at Adiana, acquired by Cytyc Corporation, leading the development and manufacturing of a complex disposable with implant and RF Generator. He also held operational management roles at Eli Lilly/Guidant Corporation supplying equipment to manufacturing sites in England, Ireland and the US. Dan has multiple patents for disposable and implant devices and completed his business degree at Illinois Central College.



### Jessy Dorn

#### VP of Clinical Affairs

Jessy Dorn, Ceribell's VP of Clinical Affairs, has over 15 years of experience in medical device clinical research. Prior to joining Ceribell in 2022, she was VP of Clinical and Scientific Research at Second Sight Medical Products, Inc. a medical device company that develops and manufactures retinal and cortical implants to create artificial vision for the blind. At Second Sight, Jessy was responsible for clinical and regulatory strategy, clinical trial design, and basic clinical research aimed at improving the safety and efficacy of visual prostheses. Jessy holds a Ph.D. in Neuroscience from UCLA and a BA in Biology from the University of Chicago.



### Kevin Kearney

#### VP of Account Management Sales

Kevin Kearney, Ceribell's VP of Account Management Sales, has over 18 years of commercial medical device leadership experience in Fortune 500 companies. Throughout his career, Kevin has specialized in bringing new innovative technologies to the market. Prior to joining Ceribell in 2019 Kevin built and successfully led several national sales teams responsible for commercializing disruptive technologies within the OR and Ophthalmology space. Most recently he was the VP of Sales for an innovative tele-health solution targeting diabetic retinopathy. He has consistently executed on delivering business results and building highly functional sales teams. Kevin holds a BA from the University of Wisconsin and a MBA from Saint Louis University.



### Rafael Donnay

#### VP of Product & Growth

Rafael Donnay, Ceribell's VP of Strategy, joined Ceribell in 2018 with over 15 years of US and international experience in the medtech industry. He started his career in engineering and product development at St. Jude Medical. He then joined Ardian (acquired by Medtronic) and helped commercialize the novel device-based treatment for hypertension in over 80 countries. Rafael then held marketing leadership roles at Stryker Neurovascular and Philips Image Guided Therapies. Rafael holds a B.S. from Columbia University, M.S. from Stanford University, and an MBA from the Wharton School of the University of Pennsylvania.